COVID-19. Probable COVID-19
Conditions
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients 18 to 65 years Resident of Qazvin Willingness to participate in the research project and complete the consent form Presence of typical evidence on lung CT-Scan or positive specific RT-PCR test from oropharyngeal secretions Presence of clinical criteria for hospitalization (fever above 38 ° C or severe cough or shortness of breath or respiratory rate greater than 24 per minute or oxygen saturation less than 93%)
Exclusion criteria
Exclusion criteria: Having a history of coagulation diseases, obesity, deep vein thrombosis Have a history of vertebral fracture or disc herniation Patients during pregnancy, lactation, and menstruation Patients with heart failure Patients with chronic renal failure cancer patients Patients with defective immune system or Patients receiving corticosteroids Existence of open wound at the site of cupping
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arterial blood oxygen saturation. Timepoint: At the beginning of the study (before the intervention) and the first to fourteenth days during cupping therapy. Method of measurement: Pulse oximetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscular pain. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score.;Headache. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score.;Chest pain. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score.;Number and severity of cough. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score.;Hemoglobin. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test.;ESR. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Sed rate device.;LDH. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Device of utoanalyser.;RDW. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test.;Platelet. Timepoint: At the beginning of t | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahyar Seddighi
Qazvin University of Medical Sciences
Outcome results
None listed